FDA Approves EFFIENT™ (prasugrel) Antiplatelet Agent

TOKYO, July 13, 2009 — Ube Industries, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Effient™ (prasugrel) for reduction of myocardial infarction in patients with acute coronary syndromes (ACS) who are managed with percutaneous coronary intervention (PCI). Effient is an oral antiplatelet agent discovered by Ube Industries and Daiichi Sankyo Co., Ltd., and co-developed for the global market by Daiichi Sankyo and Eli Lilly and Company. The announcement by Ube Industries follows a separate joint press release issued on July 10, 2009 (US Time) by Daiichi Sankyo and Lilly.

Daiichi Sankyo and Lilly will jointly launch prasugrel in the United States within the next few weeks under the trade name Effient. The European Commission has already approved prasugrel for sale in Europe on February 25, 2009, and it is currently available in the United Kingdom and other countries under the trade name Efient®. Ube Industries manufactures and supplies the active pharmaceutical ingredient for Effient, as well as Efient.

Effient works by inhibiting platelet activation and subsequent aggregation, and was developed as a new treatment for patients with acute coronary syndromes who are undergoing PCI. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke. In a large Phase III clinical trial, Effient was found to significantly reduce the risk of suffering major cardiovascular events (primarily heart attacks) compared with the current standard medication, clopidogrel. The risk of serious bleeding events was significantly higher with Effient in the overall study population, an analysis of the results finds that the risk of serious bleeding was most evident in the following patient populations: patients who weighed less than 60 kg, patients who were 75 years of age or older and patients who have had a prior transient ischemic attack (TIA) or stroke.

In its current Stage Up 2009 mid-term management plan, Ube Industries identifies the Company’s pharmaceuticals business as a developing segment with future potential for growth and profitability. Accordingly, Ube Industries is engaging in pharmaceutical R&D with the goal of discovering new and proprietary pharmaceutical agents that will benefit society.

Ube Industries co-developed the Talion® antiallergic agent with Tanabe Seiyaku Co., Ltd. (presently Mitsubishi Tanabe Pharma Corporation), and co-developed the Calblock® antihypertensive agent with Sankyo Co., Ltd. (presently Daiichi Sankyo). Talion® and Calblock® were approved and brought to market in Japan in 2000 and 2003, respectively.
Ube Industries anticipates that the marketing authorization of Efient in Europe and now approval of Effient in the U.S. will mark an important leap forward for its pharmaceutical business.

- Effient™ is a trade mark of Eli Lilly and Company.
- Efient® is a registered trademark of Eli Lilly and Company.
- Talion® is a registered trademark of Mitsubishi Tanabe Pharma Corporation.
- Calblock® is a registered trademark of Daiichi Sankyo Co., Ltd.